Aktuellt
SENASTE
At SEB's Nordic Seminar, FluoGuide CEO Morten Albrechtsen clearly laid out the equity story and discussed the path to approval and reimbursement. We were particularly interested in his thoughts about the need for flexibility in the clinical programme to be able to demonstrate clinical efficacy, superiority, and methods of use, in order to maximise reimbursement. We were also encouraged that FluoGuide's clinical program continues to be on track.
LÄS MER
